Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(applications tested for the base form of this product only)
Synthetic peptide (GEDKIKFKHITPLQEQ) corresponding to aa256-271 of human PPARg1 and aa287-302 of human PPARg2 (KLH). The immunizing sequence is identical in mouse and rat. Percent identity by BLAST analysis: Human, Gorilla, Orangutan, Gibbon, Monkey, Marmoset, Mouse, Rat, Hamster, Panda, Porcine, Cat, Bat, Dog, Horse, Rabbit, Opossum (100%); Elephant, Platypus (94%); Sheep, Goat, Bovine (88%).
Recognizes human and mouse PPARg1 and 2, Mr ~55-60kD. A non-specific protein was also detected, Mr ~47kD after longer exposure. Species sequence homology: Rat, porcine, rabbit, rhesus monkey and mink.
Suitable for use in Western Blot. Western Blot: 1-5 ug/ml of this lot detected PPARg protein in RIPA lysates from 3T3/L1 cells differentiated into adipocytes but not in undifferentiated 3T3/L1 cells.
0.1 M Tris-Glycine, pH 7.4, 0.15 M NaCl, 0.05% Sodium Azide, 30% Glycerol
Peroxisome proliferator-activated receptor gamma (PPAR gamma), a NR1 Thyroid Hormone-Like Receptor, is a transcription factor that regulates genes involved in lipid metabolism and adipocyte differentiation and has been shown to affect placental differentiation and cell proliferation and differentiation pathways in various diseases such as Type II diabetes and atherosclerosis. Recently, PPAR gamma has been suggested to affect inflammatory digestive diseases (Dubuquoy et al. 2002).